0001209191-20-013315.txt : 20200227
0001209191-20-013315.hdr.sgml : 20200227
20200227115428
ACCESSION NUMBER: 0001209191-20-013315
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200225
FILED AS OF DATE: 20200227
DATE AS OF CHANGE: 20200227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOEB GARY
CENTRAL INDEX KEY: 0001561733
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 20659742
MAIL ADDRESS:
STREET 1: 5885 HOLLIS ST., SUITE 100
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2020-02-25
2020-02-26
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001561733
LOEB GARY
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BLVD
BRISBANE
CA
94005
0
1
0
0
EVP, General Counsel & Sec.
Common Stock
2020-02-25
4
A
0
50000
0.00
A
50000
D
Stock Option (Right-to-Buy)
6.80
2020-02-25
4
A
1
100000
0.00
A
2030-02-24
Common Stock
100000
100000
D
Represents 50,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.
One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
/s/ Matthew Colvin, Attorney-in-Fact for Gary Loeb
2020-02-27